West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) Revenue
West Pharmaceutical Services, Inc.'s revenue for fiscal 2025 was $3.1B, up 6.25% from $2.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.3B. Over the past ten years it has ranged from $1.4B (fiscal 2015) to $3.1B (fiscal 2025) — the current reading is the highest in ten years. West Pharmaceutical Services, Inc. ranks 14th of 50 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.1B | 6.25% |
| FY2024 | $2.9B | (1.92%) |
| FY2023 | $2.9B | 2.18% |
| FY2022 | $2.9B | 1.95% |
| FY2021 | $2.8B | 31.89% |
| FY2020 | $2.1B | 16.69% |
| FY2019 | $1.8B | 7.13% |
| FY2018 | $1.7B | 7.40% |
| FY2017 | $1.6B | 5.96% |
| FY2016 | $1.5B | 7.81% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $872.3M | 3.24% |
| Mar 2026 | $844.9M | 4.96% |
| Dec 2025 | $805.0M | 0.05% |
| Sep 2025 | $804.6M | 4.97% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDLN Medline Inc. compare | $29.7B |
| BDX Becton, Dickinson and Company compare | $22.4B |
| BAX Baxter International Inc. compare | $11.5B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation compare | $8.3B |
| RMD ResMed Inc. compare | $5.7B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| WST West Pharmaceutical Services, Inc. | $3.3B |
| RGEN Repligen Corporation compare | $785.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on WST
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement